Ambitious efforts to catalog viruses across the globe may facilitate our understanding of viral communities and ecology, boost infectious disease diagnostics and surveillance, and spur new therapeutics.
We live in a microbial world. But can we stay healthier by manipulating the microbes that surround us?
In April, the US Food and Drug Administration cleared the first deuterated drug, Austedo (deutetrabenazine), from Teva of Petach Tikva, Israel, for the treatment of Huntington’sdisease-related movement disorders.
Can the drug industry exploit the good bugs in your gut? This article investigates clinical opportunities from targeting the “microbiome.”